Lipella Pharmaceuticals announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts. Dr. Jonathan Kaufman, CEO of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella’s new product candidate, LP-50, is intended to be indicated for non-muscle invasive bladder cancer. Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIPO:
- Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- Lipella Pharmaceuticals announces FDA Type C meeting for LP-10
- Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
- Lipella Pharmaceuticals announces FDA clearance of IND for LP-410
- Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline